Evo Alemao1, Hélène Cawston2, François Bourhis2, Maiwenn Al3,4, Maureen Rutten-van Molken3,4, Katherine P Liao5, Daniel H Solomon5. 1. Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA. 2. Real World Strategy & Analytics, MAPI, Nanterre, France. 3. Institute of Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands. 4. Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. 5. Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
Objectives: The aims were to compare the performance of cardiovascular risk calculators, Framingham Risk Score (FRS) and QRISK2, in RA and matched non-RA patients and to evaluate whether their performance could be enhanced by the addition of CRP. Methods: We conducted a retrospective analysis, using a clinical practice data set linked to Hospital Episode Statistics (HES) data from the UK. Patients presenting with at least one RA diagnosis code and no prior cardiovascular events were matched to non-RA patients using disease risk scores. The overall performance of the FRS and QRISK2 was compared between cohorts, and assessed with and without CRP in the RA cohort using C-Index, Akaike Information Criterion (AIC) and the net reclassification index (NRI). Results: Four thousand seven hundred and eighty RA patients met the inclusion criteria and were followed for a mean of 3.8 years. The C-Index for the FRS in the non-RA and RA cohort was 0.783 and 0.754 (P < 0.001) and that of the QRISK2 was 0.770 and 0.744 (P < 0.001), respectively. Log[CRP] was positively associated with cardiovascular events, but improvements in the FRS and QRISK2 C-Indices as a result of inclusion of CRP were small, from 0.764 to 0.767 (P = 0.026) for FRS and from 0.764 to 0.765 (P = 0.250) for QRISK2. The NRI was 3.2% (95% CI: -2.8, 5.7%) for FRS and -2.0% (95% CI: -5.8, 4.5%) for QRISK2. Conclusion: The C-Index for the FRS and QRISK2 was significantly better in the non-RA compared with RA patients. The addition of CRP in both equations was not associated with a significant improvement in reclassification based on NRI.
Objectives: The aims were to compare the performance of cardiovascular risk calculators, Framingham Risk Score (FRS) and QRISK2, in RA and matched non-RApatients and to evaluate whether their performance could be enhanced by the addition of CRP. Methods: We conducted a retrospective analysis, using a clinical practice data set linked to Hospital Episode Statistics (HES) data from the UK. Patients presenting with at least one RA diagnosis code and no prior cardiovascular events were matched to non-RApatients using disease risk scores. The overall performance of the FRS and QRISK2 was compared between cohorts, and assessed with and without CRP in the RA cohort using C-Index, Akaike Information Criterion (AIC) and the net reclassification index (NRI). Results: Four thousand seven hundred and eighty RApatients met the inclusion criteria and were followed for a mean of 3.8 years. The C-Index for the FRS in the non-RA and RA cohort was 0.783 and 0.754 (P < 0.001) and that of the QRISK2 was 0.770 and 0.744 (P < 0.001), respectively. Log[CRP] was positively associated with cardiovascular events, but improvements in the FRS and QRISK2 C-Indices as a result of inclusion of CRP were small, from 0.764 to 0.767 (P = 0.026) for FRS and from 0.764 to 0.765 (P = 0.250) for QRISK2. The NRI was 3.2% (95% CI: -2.8, 5.7%) for FRS and -2.0% (95% CI: -5.8, 4.5%) for QRISK2. Conclusion: The C-Index for the FRS and QRISK2 was significantly better in the non-RA compared with RApatients. The addition of CRP in both equations was not associated with a significant improvement in reclassification based on NRI.
Authors: Cynthia S Crowson; Silvia Rollefstad; George D Kitas; Piet L C M van Riel; Sherine E Gabriel; Anne Grete Semb Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240
Authors: Lotta Ljung; Peter Ueda; Katherine P Liao; Jeffrey D Greenberg; Carol J Etzel; Daniel H Solomon; Johan Askling Journal: RMD Open Date: 2018-12-16
Authors: George D Kitas; Peter Nightingale; Jane Armitage; Naveed Sattar; Jill J F Belch; Deborah P M Symmons Journal: Arthritis Rheumatol Date: 2019-07-22 Impact factor: 10.995
Authors: Jeffrey R Curtis; Fenglong Xie; Cynthia S Crowson; Eric H Sasso; Elena Hitraya; Cheryl L Chin; Richard D Bamford; Rotem Ben-Shachar; Alexander Gutin; Darl D Flake; Brent Mabey; Jerry S Lanchbury Journal: Arthritis Res Ther Date: 2020-12-04 Impact factor: 5.156
Authors: Panagiota Anyfanti; Athanasia Dara; Elena Angeloudi; Eleni Bekiari; Theodoros Dimitroulas; George D Kitas Journal: J Inflamm Res Date: 2021-12-14
Authors: Margery A Connelly; James D Otvos; Irina Shalaurova; Martin P Playford; Nehal N Mehta Journal: J Transl Med Date: 2017-10-27 Impact factor: 5.531
Authors: Evo Alemao; Maiwenn J Al; Annelies A Boonen; Matthew D Stevenson; Suzanne M M Verstappen; Kaleb Michaud; Michael E Weinblatt; Maureen P M H Rutten-van Mölken Journal: PLoS One Date: 2018-10-05 Impact factor: 3.240